Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2016

Chronic Kidney Disease payment and delivery of care reform Medicare Access and CHIP Reauthorization Act (MACRA)implementation Medicare Advantage Risk Adjustment Kidney disease quality measures H.R. 5659, ESRD Choice Act H.R. 6139, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act Comments on ESRD Prospective Payment System and Quality Incentive Program Comments on Physician Fees Schedule and MA Provider Network requirements Comments on Transplant Outcomes Measures and Organ Procurement Organization Reporting

Client expense: $65,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA), White House Office

HR 5659 Expanding Senior Receiving Dialysis Choice Act; HR 6139 Comprehensive Immunosuppresive Drug Coverage for Kidney Transplants Patient Act of 2016.

Client expense: Not reported · Firm income: $20,000